Search
Rupintrivir
go.drugbank.com/drugs/DB05102ExperimentalRupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. … Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
IR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.
16-Bromoepiandrosterone
go.drugbank.com/drugs/DB05107Investigational16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. … It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. … Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically.
Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexVIR201
go.drugbank.com/drugs/DB05110Experimentalis an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Thymectacin
go.drugbank.com/drugs/DB05116InvestigationalThymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. … Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.
IGN301
go.drugbank.com/drugs/DB05117ExperimentalIGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
AT1391
go.drugbank.com/drugs/DB05120ExperimentalAT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
1D09C3
go.drugbank.com/drugs/DB05121Experimental1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a